{"schema_version":"secwatch.filing_event.v1","accession":"0001854270-24-000027","form_type":"8-K","ticker":"SNTI","cik":"0001854270","company_name":"Senti Biosciences, Inc.","filed_at":"2024-03-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:26.035373+00:00","generated_at":"2026-06-04T10:27:33.423546+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Senti Bio reports FY2023 net loss of $71.1M; cash runway into Q1 2025; IND cleared for SENTI-202 AML therapy","bullets":["Net loss for FY2023 was $71.1M ($1.60/share) vs $58.2M in FY2022.","Cash, cash equivalents and short-term investments of $35.9M at 12/31/2023; plus $18.9M GeneFab receivable to fund into Q1 2025.","R&D expenses $32.2M (FY2023), G&A $37.2M; net loss includes $12.3M gain from discontinued operations and $25.7M impairment.","FDA cleared IND for SENTI-202 (logic-gated CAR-NK for AML); first patient dosing expected Q2 2024, initial efficacy data by year-end 2024.","Collaboration with Celest for SENTI-301A (HCC) in China; first patient dosing expected Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001854270-24-000027","json":"https://secwatch.observer/filing/0001854270-24-000027.json","markdown":"https://secwatch.observer/filing/0001854270-24-000027.md","text":"https://secwatch.observer/filing/0001854270-24-000027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1854270/000185427024000027/0001854270-24-000027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1854270/000185427024000027/snti-20240321.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T10:27:33.423546+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5e710ce9fd7ec8d2045965df7d3beb9ad3591329","claim":"Senti Biosciences, Inc. reported the year ended December 31, 2023 results: net income Net loss was $18.7 million, or $0.42 per basic and diluted share, for the quarter ended December 31, 2023. Net loss for, EPS $0.42 per basic and diluted share (quarter) and $1.60 per share (year).","evidence_excerpt":"On March 21, 2024, Senti Biosciences, Inc. issued a press release announcing its financial results for the year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1854270/000185427024000027/0001854270-24-000027-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"Net loss was $18.7 million, or $0.42 per basic and diluted share, for the quarter ended December 31, 2023. Net loss for"},{"label":"EPS","value":"$0.42 per basic and diluted share (quarter) and $1.60 per share (year)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}